Janssen
Janssen, the pharmaceutical division of Johnson & Johnson, develops, manufactures, and markets medicines across a broad range of diseases. It aims to transform patient outcomes by advancing science and delivering innovative therapies that reach the people who need them, with a commitment to improving access to medicines and providing affordable healthcare services worldwide. Through research, development, and commercialization, Janssen pursues solutions for serious conditions, translating scientific advances into practical health benefits and broad patient impact.
Top Stages
https://crunchbase.com/organization/***
https://linkedin.com/company/***
2 past transactions
Anakuria Therapeutics
Acquisition in 2022
Anakuria Therapeutics is a company recently formed by Navitor to advance its novel class of selective rapamycin analog mTORC1 inhibitors.
ViaCyte
Venture Round in 2014
ViaCyte, Inc. is a regenerative medicine company based in San Diego, California, that specializes in developing cell replacement therapies for diabetes. The company’s primary product candidates, VC-01 and VC-02, aim to treat type 1 diabetes by implanting pancreatic beta-cell precursors derived from stem cells within an encapsulation device. This innovative approach allows the implanted cells to produce insulin in response to blood glucose levels while minimizing the risk of immune rejection, thereby eliminating the need for immunosuppressants. ViaCyte's goal is to provide a long-term solution that can free both type 1 and type 2 diabetes patients from dependence on insulin and reduce associated complications such as hypoglycemia and cardiovascular issues. Founded in 1999, ViaCyte was previously known as Novocell, Inc., and changed its name in 2010. The company also operates an additional facility in Athens, Georgia.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.